Description
Release form
Dosage inhalation aerosol.
Packaging
Bottle 120 doses.
Pharmacological action
Foster has an anti-inflammatory effect, reduces the severity of symptoms of bronchial asthma and reduces the frequency of exacerbations of the disease, while it has a lower frequency of side effects than systemic corticosteroids.
Indications
Basic treatment for asthma involving combination therapy (inhaled glucocorticosteroid and 2 long-acting adrenergic agonist): Patients with symptoms of the disease that are not adequately controlled by inhaled glucocorticosteroids and 2 short-acting adrenergic agonists.
patients, receiving effective maintenance doses of inhaled glucocorticosteroids and 2 long-acting adrenergic agonists.
Contraindications
Hypersensitivity to Foster components, children under 12 years old.
Precautions: Pregnancy, lactation, pulmonary tuberculosis, fungal, viral or bacterial infections of the respiratory system, thyrotoxicosis, pheochromocytoma, diabetes mellitus, uncontrolled hypokalemia, idiopathic hypertrophic subaortic stenosis, grade III atrioventricular block, severe arterial hypertension, any localization aneurysm or other severe cardiovascular diseases (acute myocardial infarction, cardiac insufficiency, ischemic heart disease, ischemic extended Q-Tc interval (taking formoterol can cause an extension of the QTc interval)).
Use during pregnancy and lactation
There are no clinical data on the use of Foster during pregnancy. In animal studies, no embryotoxic or teratogenic effects were detected.
During pregnancy, Foster should be used only in cases where the benefits of using the drug outweigh the potential risk to the fetus. It is recommended to prescribe a minimum dose that provides effective control of symptoms of bronchial asthma.
There is no data on the penetration of Foster into breast milk of women. Foster can be prescribed to lactating women only in cases when the expected therapeutic effect for the mother outweighs the potential risk to the child.
Special instructions
It is recommended that the patient is instructed to rinse his mouth with water after inhalation of maintenance doses in order to prevent the risk of candidiasis of the oral mucosa and pharynx.
The can is under pressure: do not expose to high temperature, do not pierce, Do not throw into fire, even empty. Use within 3 months from the start of use.
Composition
1 dose of the preparation contains: Active substances: formoterol fumarate 0.006 mg
beclomethasone dipropionate 0.100 mg
Excipients: Ethanol, hydrochloric acid, norflurane (1,1,1,2-tetrafluoroethane).
Dosage and administration of
The selection of the dose of drugs that are part of Foster occurs individually and depending on the severity of the disease. For adults and adolescents over 12 years: 1-2 inhalations twice a day. Patients should be under the constant supervision of a physician to adequately select the dose of Foster. The dose should be reduced to the lowest, against the background of which optimal control of symptoms of bronchial asthma is maintained. When achieving complete control over the symptoms of bronchial asthma against the background of the minimum recommended dose of the drug, at the next stage, you can try the appointment of monotherapy with inhaled glucocorticosteroids.
There is no need for special dose selection for elderly patients.
Side effects of
Among the most common side effects associated with taking formoterol, those typical of beta2-adrenergic agonists are described, such as hypokalemia, headache, tremor, palpitations, coughing, muscle cramps, lengthening of the QTc interval. Side effects characteristic of beclomethasone dipropionate: candidiasis of the oral mucosa and pharynx, irritation in the throat.
Like other inhaled drugs, Foster can cause paradoxical bronchospasm.
Other side effects, characteristic of formoterol: thrombocytopenia, angioedema, hyperglycemia, an increase in blood levels of insulin, free fatty acids, glycerol and ketone derivatives, sleep disturbances, hallucinations, fatigue, anxiety, a change in taste (dysgeusia), tachycardia, tachychitis and stenocystitis, (coronary heart disease), atrial fibrillation, arterial hypertension, arterial hypotension, exacerbation of bronchial asthma, shortness of breath, nausea, pruritus, skin rash, urticaria, hypergi Drosis, myalgia, nephritis, peripheral edema.
Drug Interactions
B-adrenergic receptor blockers may attenuate the effects of formoterol. Foster should not be administered concurrently with b-blockers (including eye drops), except in forced cases.
overdose
Symptoms: overdose typical of beta2-adrenomimetics are symptoms caused by formoterol such as nausea, vomiting, headache, tremor, drowsiness, heart palpitations, tachycardia, gastric ulcer, gastric ulcer, gastric ulcer, .
Treatment: symptomatic treatment. In severe cases, hospitalization. The use of cardioselective beta-blockers may be considered with caution, as the use of these agents may cause bronchospasm. Monitoring of potassium level in blood plasma is required.
Inhalation of doses of beclomethasone dipropionate above recommended may cause temporary adrenal cortex suppression. Usually this does not require any emergency measures, as in most cases the normal function of the adrenal gland is restored within a few days. It is recommended that blood plasma cortisol be monitored.
When chronic administration of excessive doses of beclomethasone dipropionate may manifest its systemic effect: significant adrenal cortex suppression up to the adrenal crisis can occur. Acute adrenal crises are manifested by hypoglycemia, accompanied by confusion and / or convulsions. Situations that can serve as triggers for an acute adrenal crisis include trauma, surgery, infection or rapid reduction in the dose of Foster’s beclomethasone. In chronic overdose, it is recommended to monitor the reserve function of the adrenal cortex.
Storage conditions
In a dark place, at a temperature of 2-8 C.
Shelf life
18 months
Deystvuyushtee substance
Beclomethasone, Formoterol
Terms and conditions
prescription
dosage form
aerosol for inhalation
Prescribing
Prescribing
Adults as prescribed by a doctor
Chiesi Pharmaceuticals S.P.A., Italy
